Churchwell Insurance to Speak on D&O Insurance at Centurion One Capital 8th Toronto Conference
Dallas, Texas--(Newsfile Corp. - January 31, 2025) - Churchwell Insurance Agency (Churchwell), an industry leader and rapidly growing independent agency specializing in public companies, is proud to announce that its founder and principal, Chaz Churchwell, has been invited to speak at Centurion One Capital's (Centurion) 8th Annual Toronto Growth Conference. This premier global event will host over 500 participants, including leading companies, growth investors, and service providers from North America and abroad, from March 3-6, 2025, at the luxurious Four Seasons Hotel in Toronto.
To view an enhanced version of this graphic, please visit:
As a Gold sponsor, Churchwell is honored to partner with Centurion, widely regarded as the premier investment banking firm in Canada. Known for curating exceptional experiences and fostering meaningful connections, Centurion conferences consistently create opportunities for investors, companies, and service providers to network and thrive.
Churchwell founder and principal, Chaz Churchwell, will deliver a keynote speech titled, 'D&O Dysfunction: How Insurers Are Cheating You and Why It Will Cost You Millions.' During his presentation, qualifying companies will have the chance to enter a giveaway for a complimentary audit of their D&O insurance by one of North America's most esteemed D&O coverage attorneys.
'We are thrilled to serve as both a keynote speaker and a Gold sponsor at Centurion One Capital's prestigious Toronto Growth Conference! This opportunity affirms the trust in our team's commitment to providing top-tier service and advisement to public clients. Additionally, we plan to invest $40,000 in legal costs for the D&O coverage audits we're offering. CFOs must be equipped to confidently assure their boards that they've secured a best-in-class D&O program. These audits will provide organizations with critical insights into their current coverage.'
- Chaz Churchwell, Founder and Principal, Churchwell Insurance Agency
About Churchwell Insurance Agency:
Veteran-owned Churchwell Insurance Agency is headquartered in Dallas, TX, with an additional office in Charlotte, NC. Renowned for providing tailored insurance solutions, Churchwell specializes in helping public executives and organizations navigate complex risks. Led by experienced professionals, the agency offers comprehensive coverage options, including Directors and Officers Liability, Employment Practices Liability, Cyber Liability, Intellectual Property Insurance, and more. Churchwell serves public companies across a wide range of industries, including AI, biotech, defense, beverage, fintech, high-tech, life sciences, SPACs, and EVs. Through proactive risk management and personalized strategies, Churchwell is dedicated to safeguarding the assets and interests of its publicly traded clientele.
This version improves readability, fixes grammar and structural issues, and enhances the professional tone while maintaining your core message.
Churchwell Insurance Agency: You Build – We Protect
Media Contact:
Jerry Williams
Churchwell Insurance Agency
844.604.1357
900 S Preston Rd, Suite 50-154
Prosper, TX 75078
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 hours ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
14 hours ago
- Yahoo
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@
Yahoo
14 hours ago
- Yahoo
Data I/O Corporation (DAIO): A Bull Case Theory
We came across a bullish thesis on Data I/O Corporation (DAIO) on Breakout Investors' Substack. In this article, we will summarize the bulls' thesis on DAIO. Data I/O Corporation (DAIO)'s share was trading at $2.68 as of 30th May. A technician overseeing an application-specific integrated circuit design, etched on a metallic plate. Data I/O (DAIO) is poised for a potential turnaround after years of decline, fueled by key developments including its largest-ever adapter order and notable insider buying, particularly by newly appointed CEO William 'Bill' Wentworth. Taking the helm in October 2024, Wentworth brings over 35 years of industry expertise, with a strong track record in programming technologies and transformative leadership, notably leading Source Electronics through major acquisitions. Under his guidance, Data I/O has embarked on a strategic overhaul focused on unlocking new revenue streams, refining its go-to-market approach to emphasize customer-centric, consultative sales, and boosting operational efficiency with a renewed emphasis on high-margin consumable adapter sales. These initiatives aim to leverage the company's advanced secure programming technology and solid balance sheet to capture growth in high-potential markets such as automotive electronics and IoT. Recent financial results reinforce this positive momentum, with Q1 2025 revenues rising 19% to $6.2 million and improved EBITDA and cash balances, signaling that Wentworth's changes are driving early benefits despite a modest net loss. Data I/O's core business centers on programming semiconductor devices and securely provisioning cryptographic keys—critical for ensuring security and functionality in connected devices across automotive, industrial, and medical sectors. Innovations like VerifyBoost have significantly increased throughput, while integration tools such as ConneX Service align with Industry 4.0 demands for smart, connected manufacturing. The company's SentriX security provisioning addresses rising cybersecurity needs in IoT and automotive markets, positioning Data I/O at the forefront of secure manufacturing trends. Despite recent challenges—including a 22% revenue decline in 2024 due to global trade tensions and economic uncertainties—Data I/O's strategic focus on innovation, operational improvements, and market expansion combined with insider confidence creates a compelling case for recovery and growth. While external headwinds remain, the company's evolving product portfolio and improved execution offer a promising path to sustainable profitability and long-term value creation. Data I/O Corporation (DAIO) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 2 hedge fund portfolios held DAIO at the end of the first quarter which was 2 in the previous quarter. While we acknowledge the potential of DAIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data